Targeted Gene Correction Successfully Reverses Congenital Alpha-1 Lung and Liver Disease

For the first time, researchers have successfully corrected the genetic defect responsible for alpha-1 antitrypsin deficiency directly inside a living patient. The landmark procedure utilized precision base editing to rewrite a single DNA mutation in the patient's liver cells.[3][4]

The breakthrough, published in the Journal of Hepatology, marks a major milestone for in vivo gene therapy. It offers a potential permanent cure for a congenital metabolic disorder that progressively destroys lung and liver tissue.[4][6]

Alpha-1 antitrypsin deficiency affects an estimated 120,000 people across Europe. The condition stems from a single incorrect DNA building block that prevents the liver from producing a functional version of the protective alpha-1 antitrypsin (AAT) protein.[3]

Without this crucial protein, the body's own enzymes begin to break down lung tissue, leading to severe pulmonary emphysema. The defective, misfolded proteins also accumulate in the liver, causing fibrosis and eventually cirrhosis, which often requires an organ transplant.[3][6]

Until now, patients with the most severe form of the disease, known as the PiZZ genotype, have relied on lifelong augmentation therapy. This involves weekly intravenous infusions of the missing protein, which slows lung degradation but does not halt the disease or protect the liver.[3][4]

Precision Base Editing

To address the root cause, a collaborative team from Hannover Medical School (MHH) in Germany and Renji Hospital in Shanghai turned to an advanced form of CRISPR/Cas9 technology. Rather than introducing a functional copy of the gene via viral vectors, they repaired the existing mutation.[3]

The technique, known as base editing, acts as molecular "gene scissors" that specifically target and modify the single defective base in the DNA of the AAT-producing liver cells. This highly targeted approach avoids the risks associated with traditional gene replacement.[3][6]

"Like most congenital genetic disorders, alpha-1 antitrypsin deficiency is caused by a single tiny building block in the DNA—a so-called base—being incorrectly incorporated," explained Prof. Dr. Michael Ott, head of the Laboratory for Cell and Gene Therapy at MHH.[3]

Once the mutated base is modified, the editing tool creates a single-strand break on the opposite DNA strand. The cell then automatically initiates its natural repair program, incorporating the correct counterpart into the second strand without causing a dangerous double-strand break.[3]

The Patient Journey

The first patient to benefit from this therapy is Katrin H., a 55-year-old former anesthesiologist from Hanover. Diagnosed with the severe PiZZ genotype in 2011, she had suffered from worsening shortness of breath that eventually forced her to give up her medical career.[3]

Despite receiving weekly augmentation therapy for years, her condition continued to deteriorate. "The treatment didn't help much; the disease has continued to progress slowly and relentlessly," she noted, prompting her to seek out the experimental trial.[3]

Because the disease is rare in Asia, the Chinese biotechnology company holding the patents for the improved base-editing method funded the treatment of seven patients. In March 2026, Katrin traveled to Shanghai for a four-week stay to receive the intravenous gene therapy.[3]

The results were immediate and profound. Subsequent blood tests revealed that her liver was successfully producing functional AAT protein on its own. She experienced no side effects and has not required a single augmentation infusion since the procedure.[3]

Genomic Safety Confirmed

A follow-up liver biopsy provided unprecedented insight into the therapy's genomic safety and precision. The analysis confirmed high correction efficiency at the lowest planned dose, with no detectable "bystander" edits or off-target genetic alterations.[4][6]

The treatment effectively converted the patient's disease-causing homozygous PiZZ genotype into a healthy mosaic of fully corrected and partially corrected cells. Researchers noted that correcting more than 50% of the alleles is sufficient to significantly reduce the risk of future organ damage.[4][6]

"The high correction efficiency and remarkable precision at such a low dose were truly surprising—and highly encouraging for future applications," said Dr. Simon Krooss, a physician and scientist at the Clinical Department of Gastroenterology at MHH.[4][6]

While the gene correction cannot reverse the structural lung and liver damage that had already occurred over the past decade, it halts the progression of the disease. For Katrin, the stabilization means she can maintain her current quality of life and continue working in hospital hygiene.[3]

A Blueprint for Liver Diseases

The success of this in vivo base editing trial opens the door to treating a wide range of other hereditary liver disorders. Conditions driven by single-base mutations, including various coagulation diseases, could theoretically be cured using the exact same delivery and editing framework.[4][6]

"This is a transformative moment," Prof. Ott stated. "We are now a step closer to offering permanent, minimally invasive therapies to many patients with hereditary liver diseases."[4][6]

With rapid advances in non-viral delivery technologies, researchers believe the approach may soon extend beyond the liver to target genetic defects in other organs. The ability to safely edit the genome inside a living human represents a paradigm shift in molecular medicine.[4][6]

To make the therapy more accessible, Hannover Medical School plans to resume clinical trials locally in Germany by early 2027. Patients will no longer need to travel internationally to access the potentially life-saving genetic correction.[3]